Article
Hematology
Alexander Cohen, Virginia Noxon, Amol Dhamane, Robert Bruette, Shrushti Shah, Dionne M. Hines, Tamuno Alfred, Xuemei Luo
Summary: This study compared the risks of recurrent venous thromboembolism (VTE), major bleeding (MB), and clinically relevant non-major bleeding (CRNMB) among cancer patients with brain cancer and other types of cancer who initiated apixaban, low molecular weight heparin (LMWH), or warfarin. The results showed that apixaban was associated with a lower risk of these adverse events compared to LMWH and warfarin, and there were no significant differences in the anticoagulant treatment effects between patients with brain cancer and those with other cancer.
THROMBOSIS RESEARCH
(2023)
Article
Hematology
Philippe Girard, Silvy Laporte, Celine Chapelle, Nicolas Falvo, Lionel Falchero, Nicolas Cloarec, Isabelle Monnet, Alexis Burnod, Pascale Tomasini, Carine Boulon, Philippe Debourdeau, Bettina Boutruche, Florian Scotte, Anne Lamblin, Guy Meyer
Summary: In this prospective study of cancer patients receiving tinzaparin for VTE, the Ottawa risk score failed to accurately predict recurrent VTE. The overall 6-month cumulative incidence of recurrent VTE was 7.3%, with lower and higher risk groups having incidence rates of 5.0% and 9.1% respectively. The C-statistic value for the Ottawa score was 0.60.
THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Education, Scientific Disciplines
Bo Liang, Yi Liang, Li-Zhi Zhao, Yu-Xiu Zhao, Ning Gu
Summary: Rivaroxaban is effective in reducing recurrent VTE and shows good safety outcomes in cancer patients. Further randomized controlled trials are needed to confirm these results.
Article
Hematology
Walter Ageno, Maria Cristina Vedovati, Ander Cohen, Menno Huisman, Rupert Bauersachs, Gualberto Gussoni, Cecilia Becattini, Giancarlo Agnelli
Summary: The Caravaggio study showed that apixaban is a safe alternative to LMWH for the treatment of CAT patients, without an increased risk of gastrointestinal bleeding.
THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Biochemistry & Molecular Biology
Wei Seng Chng, Aaron Wei Liang Li, Jasmine Jia Min Lim, Esther Jia En Leong, Fathiah S. Amran, R. Manjunatha Kini, Mark Yan Yee Chan, Cho Yeow Koh
Summary: The study found that Fasxiator can be used as an anticoagulant drug and its inhibition of FXIa is promising. It has the potential to be developed as a FXIa-targeting anticoagulant.
Article
Cardiac & Cardiovascular Systems
Geraldine Poenou, Emmanuel Toledano, Helene Helfer, Ludovic Plaisance, Florent Happe, Edouard Versini, Nevine Diab, Sadji Djennaoui, Isabelle Mahe
Summary: This study evaluated the application of existing risk models in VTE patients with cancer in real-life settings, aiming to describe the bleeding of cancer patients with VTE and evaluate the performance of different bleeding models in predicting bleeding risk during a 6-month follow-up. The results showed that none of the existing risk models were able to accurately identify patients at risk of anticoagulant-associated bleeding events.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Oncology
Suguru Odajima, Toshiyuki Seki, Sayako Kato, Keisuke Tomita, Yuichi Shoburu, Eitaro Suzuki, Masataka Takenaka, Motoaki Saito, Hirokuni Takano, Kyosuke Yamada, Aikou Okamoto
Summary: Edoxaban has been found to be effective and safe for the treatment of gynecological cancer-associated thromboembolism. The study shows that there is no significant difference in recurrence rates or adverse events between edoxaban and vitamin K antagonist (VKA) treatment. Initial unfractionated heparin (UFH) therapy prior to administration of edoxaban may not be necessary for patients without pulmonary embolism (PE).
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Hiroki Ueyama, Hirotaka Miyashita, Hisato Takagi, Christina Cruz, Alfred Burger, Alexandros Briasoulis, Toshiki Kuno
Summary: DOACs can significantly reduce recurrent VTE compared to LMWH and VKA in patients with CAT, with similar bleeding risks.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2021)
Article
Health Care Sciences & Services
Yeo Jin Choi, Yong Won Choi, Jung-woo Chae, Hwi-yeol Yun, Sooyoung Shin
Summary: The study found that NOACs had significant effects in preventing VTE complications, especially deep vein thrombosis events, compared to no-use. The effects of NOACs were significant in male and female cancer patients as well as those with a Khorana score =1. Additionally, the risk of adverse bleeding was lower in patients receiving NOACs.
RISK MANAGEMENT AND HEALTHCARE POLICY
(2021)
Review
Oncology
Shuyi Wu, Meina Lv, Jiana Chen, Shaojun Jiang, Mingrong Chen, Zongwei Fang, Zhiwei Zeng, Jiafen Qian, Wenlin Xu, Chengfu Guan, Jinhua Zhang
Summary: This study analyzed 15 randomized controlled trials involving 6162 patients and found that apixaban is the most effective and safest drug for preventing and treating VTE, with relatively low bleeding risk compared to other medications.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Cardiac & Cardiovascular Systems
Tiffany Guan, Arianna Laguna, Alisha Soares, Carlo S. Legasto, Shanna Block, Ila M. Saunders, Kathryn Alvarez, Tiffany Pon, Nimish Patel, Anjlee Mahajan, Angela Lee
Summary: This study compared the safety and effectiveness of DOACs and LMWHs in the treatment of CA-VTE in patients with GI malignancies. The results showed that there was a difference in bleeding events between DOAC and LMWH, but DOAC did not increase the risk of bleeding. Careful selection of DOAC therapy is still needed for bleeding risk.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2023)
Article
Hematology
Lauren Laderman, Krishnalatha Sreekrishnanilayam, Ramesh K. K. Pandey, Elizabeth Handorf, Aryeh Blumenreich, Kristen A. A. Sorice, Shannon M. M. Lynch, Khadija Cheema, Lavanya Nagappan, Iberia R. R. Sosa, Efrat Dotan, Namrata Vijayvergia
Summary: Background: Pancreatic cancer (PC) has a high risk of venous thromboembolism (VTE), but there is a lack of verified risk assessment models (RAMs) for metastatic pancreatic cancer (mPC). Methods: This retrospective study investigated a cohort of mPC patients treated at an academic cancer center and found a VTE incidence of 17.5%. Survival analysis showed that VTE predicted poorer outcomes, with a median OS of 10.5 months in the VTEmets group compared to 13.4 months in the non-VTE group. Advanced stage disease was identified as the strongest risk factor. Conclusions: These results highlight the significant burden of VTE in mPC and the importance of risk stratification and thromboprophylaxis in this population.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Parwana Hussaini, Trine-Lise Larsen, Waleed Ghanima, Anders Erik Astrup Dahm
Summary: This study analyzed the incidence and risk factors for bleeding in cancer patients with venous thromboembolism (VTE) treated with apixaban. The results showed that the incidence of clinically relevant bleedings was highest during the first 6 months of treatment, and decreased over time. Age above 74 years, low body mass index (BMI), and low hemoglobin levels were associated with increased risk of bleeding during the first 6 months. Gastrointestinal or urogenital cancer was not associated with increased risk of bleeding compared to other cancers. In patients with luminal gastrointestinal cancer, nonresected cancer had a higher risk of bleeding compared to resected cancer.
THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
F. Abu Saadeh, Z. Marchocki, S. A. O'Toole, N. Ibrahim, N. Gleeson, L. A. Norris
Summary: The study found that extended prophylaxis did not significantly reduce VTE rates in gynaecological cancer patients post surgery. In many patients receiving a fixed LMWH dose, peak anti-Xa levels may be suboptimal.
THROMBOSIS RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Shohei Migita, Yasuo Okumura, Ikuo Fukuda, Mashio Nakamura, Norikazu Yamada, Morimasa Takayama, Hideaki Maeda, Takeshi Yamashita, Takanori Ikeda, Makoto Mo, Tsutomu Yamazaki, Atsushi Hirayama
Summary: In this study, the clinical outcomes of 949 Japanese patients with VTE were examined. It was found that patients with high D-dimer concentration had a higher incidence of clinically relevant events and a significant difference in the incidence of ischemic stroke compared to patients with low D-dimer concentration. Therefore, elevated D-dimer concentration may be an important prognostic predictor in Japanese patients with VTE.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
